secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-07-19T23:59:59+00:00
Accession:  0001140361-23-035123
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics receives FDA approval for ninth plasma collection center in Dallas, GA
--------------------------------------------------------------------------------

- FDA approved Dallas, GA facility's BLA; center began plasma collection in Q3 2022.
- Facility now licensed to collect and ship source plasma interstate for manufacturing.
- Company on track to have all 10 centers FDA-licensed by year-end 2023.
- Supports plasma self-sufficiency, revenue growth, and profitability outlook.
- Facility features Haemonetics NexSys Persona system; expects staff of 50 at capacity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123035123/0001140361-23-035123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123035123/brhc20056054_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-035123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer